Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
November 09 2022 - 8:00AM
Esperion (NASDAQ: ESPR) will host a virtual R&D Day for the
investment community today, Wednesday, November 9 at 10:00 AM
Eastern time.
The R&D Day presentation will feature discussions led by
global scientific leaders Professor Peter Libby, MD, from Brigham
and Women’s Hospital and Harvard Medical School, and C. Michael
Gibson, MS, MD, from Harvard Medical Research Institutes. In
addition, key members of the Esperion research and development
leadership team will provide an overview of its planned scientific
focus and future growth drivers.
“We are pleased to host such prominent scientific experts in
cardiology to lead discussions highlighting unmet needs and future
directions in medical research,” said Sheldon Koenig, President and
CEO of Esperion. “With CLEAR Outcomes on track and approaching
completion, today’s R&D Day is an opportunity to review the
opportunities with CLEAR Outcomes as well as our strategic vision
for our robust pipeline of differentiated assets during this
transformative time for the Company. We believe that our
significant body of work on bempedoic acid provides important
clinical validation for inhibition of the ACLY pathway, and next
generation ACLY inhibitors have potential to benefit patients with
conditions extending beyond cardiovascular disease, including
hepatorenal and metabolic diseases, inflammation and cancer.”
The R&D Day agenda includes the following presentations:
- Sheldon Koenig, President and CEO of Esperion
will present an overview of Esperion’s focus for today, tomorrow,
and the future.
- JoAnne M. Foody, MD, FACC, FAHA, Esperion’s Chief
Medical Officer will highlight the state of global
cardiovascular health and the opportunities for Esperion’s pipeline
programs, including CLEAR Outcomes.
- C. Michael Gibson, MS, MD, will discuss the
importance of lowering LDL-cholesterol levels, the role of
bempedoic acid in reaching LDL-C goals and an overview of CLEAR
Outcomes.
- Peter Libby, MD, will discuss the role of
inflammation as a common pathway and potential target in major
chronic diseases, including cardiovascular disease and cancer.
- Stephen Pinkosky, PhD, Esperion’s Executive Director of
R&D will present Esperion’s pipeline strategy and
vision for its oral PCSK9 inhibitor program and next generation ATP
citrate lyase inhibition (ACLYi) platform.
A live Q&A session will follow the formal presentations. To
register for the webinar, please click here. A replay of the
webcast will be available following the presentation on the
investors and media section of Esperion’s website.
CLEAR OutcomesCLEAR Outcomes is a Phase 3,
event-driven, randomized, multicenter, double-blind,
placebo-controlled trial designed to evaluate whether treatment
with NEXLETOL reduces the risk of cardiovascular events in patients
with or who are at high risk for cardiovascular disease with
documented statin intolerance (inability to tolerate 2 or more
statins, one at a low dose) and elevated LDL-C levels (fasting
blood LDL-C ≥ 100 (2.6 mmol/L). The study, which includes over
14,000 patients at over 1,200 sites in 32 countries, accumulated
the targeted 1,620 primary major adverse cardiovascular events
(MACE-4) in August 2022.
Esperion Therapeutics
Esperion works hard to make our medicines easy to get, easy to
take and easy to have. We discover, develop, and commercialize
innovative medicines and combinations to lower cholesterol,
especially for patients whose needs are not being met by the status
quo. Our entrepreneurial team of industry leaders is inclusive,
passionate, and resourceful. We are singularly focused on managing
cholesterol so you can improve your health easily. For more
information, please visit www.esperion.com and follow us on
Twitter at www.twitter.com/EsperionInc.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding marketing strategy and commercialization
plans, current and planned operational expenses, future operations,
commercial products, clinical development, including the timing,
designs and plans for the CLEAR Outcomes study and its results,
plans for potential future product candidates, financial condition
and outlook, including expected cash runway, and other statements
containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,” and
similar expressions. Any express or implied statements contained in
this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Forward-looking
statements involve risks and uncertainties that could cause
Esperion’s actual results to differ significantly from those
projected, including, without limitation, the impact of the ongoing
COVID-19 pandemic on our business, revenues, results of operations
and financial condition, the net sales, profitability, and growth
of Esperion’s commercial products, clinical activities and results,
supply chain, commercial development and launch plans, and the
risks detailed in Esperion’s filings with the Securities and
Exchange Commission. Any forward-looking statements contained in
this press release speak only as of the date hereof, and Esperion
disclaims any obligation or undertaking to update or revise any
forward-looking statements contained in this press release, other
than to the extent required by law.
Contact:Esperion Corporate
Communicationscorporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From May 2024 to Jun 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2023 to Jun 2024